MAPT and Alzheimer disease: This advancement has already led to important discoveries in human AD; including the identification of a new potential AD biomarker, pT217-tau, in human cerebrospinal fluid (Barthélemy et al., 2020a; Janelidze et al., 2020) and plasma (Palmqvist et al., 2020).